Novartis Reports Positive 48-Week Results for Fabhalta in PNH Trial

Novartis Reports Positive 48-Week Results for Fabhalta in PNH Trial

Novartis Pharmaceuticals Corporation has released new 48-week results from the Phase III APPLY-PNH trial, showcasing sustained efficacy and long-term safety…

Read More »